Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions
All Solid Tumors
Interventions
BIOLOGICAL

MET-4

Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NuBiyota

OTHER

lead

University Health Network, Toronto

OTHER

NCT03686202 - Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients | Biotech Hunter | Biotech Hunter